CDMO Market Insight, Pricing and Benchmarking Reports

NICE INSIGHT REPORT

PlasmidsMarket Insight, CDMO Pricing and Competitor Benchmarking

Coming February 2025

2025 pDNA CDMO pricing data and benchmarking report
Over 20 capability profiles of CDMOs specializing in pDNA
Over 800 hours worth of research in pDNA manufacturing market intelligence
Scientific analysis of pDNA as both a reagent and a primary therapeutic
Essential market insights for CDMOs, innovators and investors

Contact Sales

Key market intelligence for innovators, CDMOs and investors in the pDNA market.

Scientific analysis of pDNA and Advanced Therapeutics

Stay up to date with market trends for plasmid DNA (pDNA) as both a reagent for advanced therapies and as a primary therapeutic. Our Market Insight report provides essential market intelligence from innovators, CDMO owners, PhDs and researchers across advanced therapeutics to fully understand plasmids’ role in advanced therapeutics.

Exclusive CDMO pricing data for benchmarking

Measure your business against your peers using our robust analysis of the pDNA contract development and manufacturing market. Our pricing matrix comprises material cost, infrastructure and development process data from across the industry so you can make informed decisions to best position your business.

Essential price benchmarking, scientific analysis and market intelligence for Plasmid DNA manufacturing — all in one report.

Contact Sales

The Plasmids: Market Insight, CDMO Pricing and Competitor Benchmarking provides

/hubfs/2024%20Reports/09_Plasmids/01%20pricing%20data%20icon%2065x65@2x.png

Competitive benchmarking data from pDNA CDMOs all over the world

/hubfs/2024%20Reports/09_Plasmids/02%20profiles%20icon%2065x65@2x.png

20+ company profiles of companies specializing in pDNA

/hubfs/2024%20Reports/09_Plasmids/03%20scientific%20analysis%20icon%2065x65@2x.png

Scientific analysis of the pDNA development and manufacturing process

/hubfs/2024%20Reports/09_Plasmids/04%20benefits%20icon%2065x65@2x.png

Unique benefits and complexities of pDNA as both a starting material and primary therapeutic

/hubfs/2024%20Reports/09_Plasmids/05%20investment%20outlook%20icon%2065x65@2x.png

Investment outlook of the pDNA market — analyzing economic and regulatory conditions around advanced modalities

/hubfs/2024%20Reports/09_Plasmids/06%20innovations%20icon%2065x65@2x.png

Innovations and breakthroughs that are powering pDNA-based therapeutics

Over 800 hours of data collection and analysis from

interviews, primary research and progressive study.